Good correlation between the Afinion AS100 analyser and the ABX Pentra 400 analyser for the measurement of glycosylated haemoglobin and lipid levels in older adults in Durban, South Africa by Abbai, N S et al.
50       January 2018, Vol. 108, No. 1
RESEARCH
Globally, 18 million people die annually from cardiovascular disease 
(CVD).[1] Findings from the INTERHEART Africa study[2] indicated 
that the highest number of premature acute myocardial infarctions 
in the world occur in sub-Saharan Africa, as a result of lack of early 
detection of CVD and effective management of risk factors.[3] Various 
point-of-care (POC) tests (mainly finger-prick tests) are available 
that provide results ranging from total cholesterol (TC) alone to a full 
lipogram. However, the limitation with many of these tests is that the 
results obtained are not adequate to commit a patient to a lifetime of 
therapy. In addition, finger-prick testing that measures TC alone will 
not detect raised triglycerides.[3]
Patients with diabetes mellitus (DM) are at high risk of developing 
CVD, with increased associated mortality.[4] In many primary care 
settings, testing for glycaemic control involves sending a blood sample 
away for laboratory testing and waiting a number of days for the 
result to be returned. This delays patient counselling and treatment 
adjustments based on glycated haemoglobin (HbA1c) levels, and 
sometimes follow-up can be lost completely.[4] Measurement of 
HbA1c levels using POC tests provides rapid results, improving 
patient management.[4-6] Findings from a randomised controlled 
trial of POC testing in an Australian setting showed that POC 
tests of samples from patients with established hyperlipidaemia or 
established type 1 or type 2 DM, or taking anticoagulant therapy, had 
the same clinical effectiveness as testing in a pathology laboratory.[7] 
Reports have also shown that access to a POC test is associated with 
improved treatment adherence.[8]
The Afinion AS100 analyser (Alere, South Africa (SA)) is a small 
bench-top, multi-assay analyser for in vitro diagnostic POC testing 
using whole blood, plasma or urine samples. The unique feature of 
the analyser is that both the HbA1c and the lipid panel test can be 
done on one instrument. The turnaround time from collection of 
samples to all results being available to the patient is <30 minutes.
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Background. The Afinion AS100 analyser is a small bench-top, multi-assay, point-of-care (POC) analyser that is able to measure glycated 
haemoglobin (HbA1c) and lipid levels.
Objective. To assess performance of the Afinion analyser compared with a reference laboratory test for the measurement of HbA1c and 
lipid levels.
Method. The study involved men and women enrolled in a cross-sectional study, Sexual health, HIV infection and comorbidity with 
non-communicable diseases among Older Persons (SHIOP), which was conducted from February to May 2016. Whole blood was drawn 
aseptically by a trained study nurse into a serum separator gel tube and an ethylenediaminetetra-acetic acid (EDTA) tube. The EDTA whole 
blood was used to measure HbA1c levels, and serum to measure total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C) and triglyceride levels. Lin’s correlation coefficient was used to assess the agreement between the 
Afinion and ABX Pentra 400 analysers for each marker.
Results. A total of 435 older individuals were included in the study. The proportion of HbA1c results that were correctly classified by the 
Afinion analyser was 92.2%. Bland-Altman analysis and linear regression analysis showed a very good agreement (correlation concordance 
0.89) between the two analysers for the measurement of HbA1c. The two-way scatter plot for TC showed a substantial correlation (0.80). 
However, a total of 69 cholesterol results that were within the normal range on the Pentra were misclassified as abnormal on the Afinion. The 
readings obtained for HDL-C levels with the Afinion were shown to be slightly overestimated when compared with the Pentra. However, 
correlation for HDL-C on the two analysers was 0.93, indicating an almost perfect agreement. Seventy-four LDL-C results were erroneously 
classified as abnormal on the Afinion but were within the normal range on the Pentra, resulting in a substantial correlation of 0.75. An 
excellent agreement was observed between triglyceride measurements (0.99).
Conclusion. This study supports the use of the Afinion AS100 analyser in POC testing for the measurement of HbA1c, triglycerides and 
HDL-C in a South African setting.
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Preliminary results from a recent study on sexual health and chronic 
morbidities in people aged ≥50 years conducted in the Chatsworth 
and Botha’s Hill areas of Durban, SA, found that >70% of older 
adults had elevated blood glucose levels indicating prediabetes and 
diabetes, and that over half of the study participants had elevated 
blood pressure readings (unpublished data). In addition, >15% of 
the study participants were HIV-infected, which is higher than the 
national average.[9] There is therefore an urgent need to respond to 
the growing twin health challenges of HIV and non-communicable 
diseases among older adults.
Objective
To evaluate the performance of the lipid and HbA1c panels of 
the Afinion AS100 analyser compared with standard laboratory 
methods in a population of HIV-positive and HIV-negative older 
adults.
Methods
Study participants
The study was a sub-analysis of a cross-sectional study, Sexual health, 
HIV infection and comorbidity with non-communicable diseases 
among Older Persons (SHIOP). The SHIOP study enrolled both men 
and women and was conducted between February and May 2016. 
The primary aim of SHIOP was to describe sexuality, sexual health 
and the comorbidity of HIV and sexually transmitted infections with 
chronic non-communicable diseases in adults aged ≥50 years in a 
setting of high HIV prevalence. Participants were recruited from two 
sub-areas of Durban (Botha’s Hill and Chatsworth), SA. Botha’s Hill is 
a semi-rural area located west of Durban, and Chatsworth is an urban 
setting located south of Durban. The study eligibility criteria included 
age ≥50 years, being willing and able to provide written informed 
consent and able to communicate in English or isiZulu, and not being 
terminally ill or cognitively impaired.
Ethical considerations
As part of the study procedure, all study participants provided 
written informed consent prior to enrolment. Participants who 
were illiterate (i.e. unable to read or write English or isiZulu), were 
assisted by an impartial literate witness during the informed consent 
process. The participant used a thumbprint to mark the informed 
consent form and the impartial witness signed to confirm that 
the participant provided informed consent. We followed the usual 
procedure adopted in large-scale multi-site HIV prevention clinical 
trials. Ethical approval for SHIOP was obtained from the South 
African Medical Research Council (SAMRC) Ethics Committee (ref. 
no. EC030-9/2015).
Sample collection and processing
All eligible participants were requested to provide a venous blood 
sample for laboratory testing. Whole blood was drawn aseptically 
by a trained study nurse into a serum separator gel tube and an 
ethylenediaminetetra-acetic acid (EDTA) tube. The serum gel tube 
was centrifuged at the research clinics and the separated serum used 
for measuring lipid levels, and the EDTA whole-blood tube was used 
to measure HbA1c levels using the POC Afinion AS100 analyser, 
which was placed at the research clinics. The remaining serum and 
EDTA whole blood was transported on ice on the day of collection 
to the SAMRC HIV Prevention Research Unit’s central routine 
laboratory for measurement of blood glucose and lipid levels on the 
ABX Pentra 400 analyser (Horiba, USA). All testing was performed 
by trained medical technologists.
POC testing using the Afinion analyser
HbA1c measurements
HbA1c levels were measured using 1.5 µL of EDTA whole blood.  The 
Afinion works on the boronic acid affinity test principle and is not 
affected by haemoglobin variants. The analyser claims a 4.0 - 15.0% 
(20.0 - 140.0 mmol/mol) HbA1c measuring range. The assay time 
was ~3 minutes, and controls with HbA1c-specific target values were 
included in the assay runs.
Lipid measurements
TC, low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C) and triglycerides were measured 
using 1.5 µL of serum. The assay time was ~8 minutes, and ready-to-
use control material was included in the assay runs. The measuring 
ranges for lipids using the Afinion analyser were as follows: TC 2.59 - 
12.95 mmol/L, HDL-C 0.39 - 2.59 mmol/L, and triglycerides 0.51 - 
7.34 mmol/L. LDL-C was a computed value using the Friedewald 
formula[10,11] LDL-C (mmol/L) = TC – HDL-C – triglycerides/2.2.
Reference laboratory testing
The Pentra analyser was used as the reference laboratory test 
according to the manufacturer’s instructions. According to SA 
national guidelines, the reference (normal) range for testing and 
management of lipids is as follows: TC <4.5 mmol/L, LDL-C 
<2.5  mmol/L, HDL-C 1.0 mmol/L (men) and ≥1.2 mmol/L (women), 
and triglycerides <1.70 mmol/L. The diagnostic cut-off for HbA1c is 
6.5% (or 48 mmol/mol). We used these reference ranges to compare 
participants categorised as normal v. abnormal on the Pentra and 
Afinion for each marker.
Data analysis
Lin’s correlation coefficient was used to assess the agreement between 
the Afinion and Pentra analysers for each marker. The mean bias 
was calculated, as well as the 95% limits of agreement to quantify the 
difference between a reading on the Afinion and the Pentra. Results 
were graphically depicted using Bland-Altman plots and two-way 
scatterplots. The coefficients were classified as indicating poor (<0.69), 
fair (0.70 - 0.79), good (0.80 - 0.89) or excellent (0.90 - 1.00) correlation.
Results
Sample description
We obtained data on 435 older adults from Durban, SA. The overall 
median age of the study participants was 61 years (interquartile 
range 12), with male participants being slightly older than female 
participants (62 v. 60 years). Using World Health Organization 
categorisations of clinically assessed weight and height, ~60% of 
study participants were overweight or obese, and ~40% (n=172) were 
hypertensive. Furthermore, 16.1% of participants (n=70) were HIV-
positive, of whom 84.3% (n=59) knew their HIV status prior to study 
participation (data not shown).
Diagnostic accuracy of the Afinion v. the Pentra analysers
Table 1 describes the diagnostic performance of the Afinion analyser 
for the measurement of HbA1c, TC, LDL-C, HDL-C and triglyceride 
levels in comparison with the Pentra. In addition, the differences 
between the Afinion and Pentra measurements using Bland-Altman 
plots are described in Table 2 and Figs 1 - 5.
HbA1c levels
The proportion of HbA1c results that were correctly classified by the 
Afinion analyser was 92.2% (Table 1). We also observed high diagnostic 
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accuracy of the Afinion in detecting results 
that were above target levels, as indicated 
by both sensitivity and specificity >90%. 
According to our analysis, higher values for 
HbA1c levels were detected with the Afinion 
than with the Pentra. Bland-Altman analysis 
and linear regression analysis showed an 
almost excellent agreement between the two 
analysers (Fig. 1). A correlation of 0.89 was 
observed (Table 2).
Lipid levels
The proportion of TC results that were 
correctly classified by the Afinion analyser 
was 79.3% (Table 1). The TC two-way 
scatter plot represented in Fig. 2 showed 
a good correlation (0.80) between the two 
analysers. However, a total of 69 TC results 
that were within the normal range on the 
Pentra were misclassified as abnormal on 
the Afinion, leading to a poor specificity 
of 63.9%.  However, the Afinion correctly 
classified all 142 results that were in the 
abnormal range on the Pentra, resulting 
in a sensitivity of 100%. The mean bias 
observed for TC measurements between 
the Afinion and the Pentra analysers was 
0.569, with 95% limits of agreement of 
–0.169 - 1.307 (Table 2).
The readings obtained for HDL-C levels 
with the Afinion were shown to be slightly 
overestimated compared with the Pentra 
(mean bias 0.089). The correlation between 
the two methods was 0.93, indicating excel-
Table 1. Diagnostic accuracy of the Afinion analyser compared with the Pentra, using target levels as cutoffs
Pentra Afinion
Normal, n Abnormal, n
Correctly 
classified, % Sensitivity, % Specificity, %
HbA1c Afinion
Normal 214 7 92.2 90.9 92.6
Abnormal 17 70      
TC Afinion
Normal 122 0 79.3 100 63.9
Abnormal 69 142      
LDL-C Afinion
Normal 126 1 76.1 99.1 63.0
Abnormal 74 113      
HDL-C, males Afinion
Normal 12 2 90.9 97.5 63.2
Abnormal 7 78      
HDL-C, females Afinion
Normal 76 5 89.9 96.3 80.9
Abnormal 18 129      
TG Afinion
Normal 158 15 95.4 91.1 100
Abnormal 0 154      
HbA1c = glycated haemoglobin; TC = total cholesterol; HDL-C = high-density cholesterol; LDL-C = low-density cholesterol; TG = triglycerides.
Table 2. Differences between the Afinion and Pentra measurements using BA plots
N Mean bias (SD) 95% BA limits of agreement Concordance correlation 
HbA1c 308 0.224 (0.840)       –1.421 - 1.870 0.89
TC 333 0.569 (0.377)      –0.169 - 1.307 0.80
LDL-C 314 0.528 (0.385) –0.227 - 1.283 0.75
HDL-C 327 0.089 (0.095) –0.097 - 0.275 0.93
TG 327 –0.124 (0.127) –0.373 - 0.125 0.99
BA = Bland-Altman; SD = standard deviation; HbA1c = glycated haemoglobin; TC = total cholesterol; HDL-C = high-density cholesterol; LDL-C = low-density cholesterol; TG = trigycerides.
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Fig. 1. Scatterplot and regression line of HbA1c values (%) produced by the Afinion (A) and Pentra (P) 
analysers. The Bland-Altman study and linear regression analysis showed good agreement between the 
two analysers. (HbA1c = glycated haemoglobin.)
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lent agreement between the two analysers 
(Fig. 3). Misclassification of HDL-C results 
was low in both males and females. The 
specificity of the Afinion test was lower in 
males, 7 of 19 HDL results that were below the 
target levels on the Pentra being incorrectly 
classified as normal by the Afinion.
LDL-C values tended to be overestimated 
by the Afinion, with a mean bias of 0.528. 
According to the analysis, 74 LDL-C results 
were erroneously classified as abnormal 
according to the Afinion but were within 
the normal range on the Pentra, giving a 
specificity of 63.0% (Table 1). Although 
poor specificity was observed, the sensitivity 
of the Afinion was 99.1%, indicating that 
the analyser performs well in detecting 
values above the target range. However, it 
is important to note that the LDL-C was 
a computed value using the Friedewald 
formula, and because it was not measured 
directly it may not be a direct reflection of the 
accuracy of the analysers used. Despite this, a 
fair correlation of 0.75 was observed between 
the two analysers (Fig. 4).
Excellent agreement was observed between 
triglycerides measured on the Afinion and 
the Pentra, evidenced by the mean bias of 
0.124 and almost perfect agreement between 
the two analysers, with a correlation of 0.99 
(Fig. 5). When categorising values according 
to target levels, excellent diagnostic accuracy 
was observed, with a sensitivity of 91.1% and 
specificity of 100%.
Discussion
The objective of this study was to evaluate 
the performance of the Afinion AS100 
analyser compared with a standard labora-
tory method for the measurements of 
lipids and HbA1c in a population of HIV-
positive and HIV-negative older adults. 
Overall, Bland-Altman plots revealed a 
good correlation between the Afinion and 
Pentra 400 analysers for the measurement 
of HbA1c levels.  In addition, the Afinion 
was able to correctly classify >90% of the 
samples. With regard to the measurement 
of lipid levels, the results showed very good 
correlation between the Afinion and the 
Pentra, with almost perfect correlations 
noted for HDL-C and triglycerides.
HbA1c measurement is an important 
tool in the management of patients with 
DM. Evidence for the utility of HbA1c 
for the diagnosis and detection of DM 
in an SA population has been described 
by Hird et al.[12] However, in SA primary 
healthcare facilities, random blood glucose 
measurement is commonly used to make 
clinical decisions with regard to glycaemic 
control, as HbA1c tests have not been done 
or the results are not yet available or are out 
of date.[13] In addition, the DiabCare Africa 
study found that <50% of patients with 
DM had had an HbA1c test as part of their 
management during the previous year. [12] 
To this end, the availability of a rapid and 
accurate method of HbA1c evaluation is 
of paramount importance.[14] According to 
Gaziano et al.,[15] since the late 1990s, deaths 
due to non-communicable diseases have 
increased steadily in adults aged ≥50 years. 
A number of risk factors contributing to 
mortality, such as hypertension, increased 
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Fig. 2. Scatterplot and regression line of TC values (mmol/L) produced by the Afinion (A) and Pentra 
(P) analysers. The Bland-Altman study and linear regression analysis showed a substantial agreement 
between the two analysers. (TC = total cholesterol.)
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Fig. 3. Scatterplot and regression line of HDL-C values (mmol/L) produced by the Afinion (A) and 
Pentra (P) analysers. The Bland-Altman study and linear regression analysis showed an almost perfect 
agreement between the two analysers. (HDL-C = high-density lipoprotein cholesterol.)
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Pentra (P) analysers. The Bland-Altman study and linear regression analysis showed a substantial 
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smoking prevalence, dietary changes and 
obesity, have been identified. These risk 
factors have also led to increases in symp-
tomatic cardiovascular conditions such as 
stroke, ischaemic heart disease and DM, 
to which health policy makers have yet to 
provide an effective response. The global 
diagnostics industry is growing rapidly, since 
new diagnostic platforms have advanced 
modern healthcare in terms of the accuracy 
(sensitivity, specificity and reproducibility), 
speed and scope of diagnoses.[16]
The present study revealed a good 
correlation between the Afinion and Pentra 
analysers for the measurement of HbA1c 
levels.  Our findings are supported by other 
published studies. A study by Lenters-
Westra et al.[17] evaluated seven point-of-care 
analysers for HbA1c (DCA Vantage, Afinion, 
Innova Star, Quo-Lab, Quo-Test, Cobas B101, 
B-analyst). The Afinion passed the National 
Glycohemoglobin Standardization Program 
(NGSP) criteria with two different lot 
numbers. In addition, the Afinion remained 
unaffected by the common haemoglobin 
variants. The study concluded that the 
Afinion met the performance criteria for 
HbA1c.[12] Previous studies on the diagnostic 
accuracy of the Afinion have been conducted 
on paediatric samples, as described by Wood 
et al.[18] In this study, the Afinion’s accuracy 
and precision was compared with high-
performance liquid chromatography (HPLC) 
and DCA methods. The findings showed that 
the Afinion generated higher HbA1c results 
when compared with HPLC, while the DCA 
produced lower values. At high HbA1c levels, 
the DCA tended to read lower than HPLC, 
but the Afinion’s accuracy did not vary 
according to HbA1c.[18] Jain et al.[5] evaluated 
the performance of the Afinion in a DM and 
CVD screening programme. In this study, 
the Afinion and the reference laboratory 
method identified similar numbers of new 
patients with suspected DM. In the present 
study, the researchers also found that the 
Afinion detected HbA1c levels that were 
above target levels. Similar findings were 
reported by Jain et al.,[5] with the Afinion 
being shown to overestimate HbA1c levels 
for certain samples. However, similar to the 
present study, the overestimation did not 
affect the overall diagnostic performance of 
the instrument. The Afinion is still recom-
mended as a useful screening instrument for 
DM in a community setting, but diagnosis 
needs to be confirmed by an NGSP-certified 
method.[5]
In SA, since the prevalence of familial 
hypercholesterolaemia is as high as 1 in 100 in 
some communities, ideally everyone should 
undergo a full lipogram, or at minimum 
TC/LDL-C measurement, at least once in 
young adulthood (from 20 years of age). [3] 
Although the measurement of lipids in the 
blood is a widely accepted biochemical 
marker for cardiovascular risk assessment 
and management in primary healthcare,[19,20] 
testing performed in hospital laboratories may 
result in excess travel for the patient, sample 
loss and repeat clinic visits.[19] A survey of the 
literature showed a limited number of studies 
that have investigated the performance of the 
Afinion analyser in measuring lipid levels. 
Our study is one of two suggesting that the 
Afinion is an acceptable POC tool for the 
measurement of lipids. Our findings support 
those of Jain et al.,[5] who compared the 
Afinion with the Cholestech LDX for the 
measurement of TC, HDL-C and triglyceride 
levels. The Afinion was shown to meet the 
performance criteria recommended by the 
National Education Cholestrol Program in 
the UK for TC and HDL-C measurements.[5] 
In the present study, the readings obtained for 
HDL-C levels with the Afinion were shown 
to be slightly overestimated compared with 
the Pentra. Similarly, the Afinion was shown 
to overestimate HDL-C levels in the study by 
Jain et al.[5] Despite the overestimated values 
in the present study, overall the correlation 
between the two instruments used showed an 
excellent level of agreement. Our study adds 
to the growing body of evidence regarding the 
diagnostic performance of the Afinion for the 
measurement of lipid levels.
Study limitations
A limitation of this study is that the testing 
was performed in a laboratory setting by 
trained laboratory personnel and is not 
truly representative of a primary healthcare 
clinic setting. Field studies at primary 
healthcare facilities using healthcare workers 
(nurses) to perform the testing could be a 
future research direction. The study was 
also limited to a targeted population (older 
individuals). We have provided a strong 
rationale of why we chose to work with this 
population. However, future studies may 
need to be conducted in a more general 
population group. Cost-effectiveness studies 
on the use of the Afinion in resource-poor 
settings are needed.
Conclusion
The study is unique in that it provides the 
first report on the diagnostic performance 
of the Afinion AS100 analyser in measuring 
HbA1c and lipid levels in a population of 
HIV-infected and uninfected adults aged 
≥50 years in KwaZulu-Natal Province, SA. 
In our study population there were no 
significant differences in HbA1c and lipid 
levels according to HIV status. In addition, 
there have been no reports demonstrating 
the role of HIV infection and antiretroviral 
use in affecting the diagnostic performance 
of point-of-care instruments for HbA1c 
and lipid levels. This study supports the 
use of the Afinion as a POC test for the 
measurement of HbA1c, triglycerides and 
HDL-C in an SA setting.
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